Bristol-Myers Squibb Co. (BMY)

Common-Size Statement of Financial Position, Liabilities and Stockholders' Equity

Difficulty: Beginner

Annual Data

Quarterly Data

Bristol-Myers Squibb Co., Common-Size Consolidated Statement of Financial Position, Liabilities and Stockholders' Equity

	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013
Short-term debt obligations
Accounts payable
Accrued rebates and returns
Employee compensation and benefits
Research and development
Dividends
Royalties
Branded Prescription Drug Fee
Restructuring
Pension and postretirement benefits
Litigation and other settlements
Other
Accrued liabilities	%	%	%	%	%
Deferred income
Income taxes payable
Liabilities related to assets held-for-sale
Current liabilities	%	%	%	%	%
Deferred income
Income taxes payable
Pension and other liabilities
Long-term debt, excluding current portion
Non-current liabilities	%	%	%	%	%
Total liabilities	%	%	%	%	%
Preferred stock, $2 convertible series, par value $1 per share
Common stock, par value of $0.10 per share
Capital in excess of par value of stock
Accumulated other comprehensive loss
Retained earnings
Cost of treasury stock
Total Bristol-Myers Squibb Company shareholders' equity	%	%	%	%	%
Noncontrolling interest
Total equity	%	%	%	%	%
Total liabilities and equity	%	%	%	%	%

	Bristol-Myers Squibb Co.	Other companies (not purchased previously)
Financial Statements
Common-Size Financial Statements
Ratios
Relative Valuation
Discounted Cash Flow (DCF) Valuation
Economic Value Added (EVA)
Long-term Trends
Analysis
Financial Reporting Quality

	All companies
Financial Statements
Common-Size Financial Statements
Ratios
Relative Valuation
Discounted Cash Flow (DCF) Valuation
Economic Value Added (EVA)
Long-term Trends
Analysis
Financial Reporting Quality